An interventional study of Time-Restricted Eating 16h/8h and Active Control in Menopause and Obesity and Overweight, sponsored by University Hospital, Geneva. Recruiting at 1 site in Switzerland. Open to female participants aged 45 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-01-27.
Sponsored by University Hospital, Geneva · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Obesity with a site in Switzerland — 22 open to participants now, 30 under way, 5 of them phase 3. Obesity · Switzerland.
Among the 127 studies in Obesity with a site in Switzerland, this one is the 32nd largest by planned enrollment of the 90 interventional ones that give a count, is one of 9 that started in 2025, is one of 64 with no phase, reaches primary completion later than 10 of the 29 other live ones, and was the 114th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →22 of the 127 studies in Obesity with a site in Switzerland are open now. Recruiting first, the newest first:
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 18–60 · Healthy volunteers
University Hospital, Geneva · Sites in Switzerland
Amgen · Sites in Switzerland, United States, Argentina and 32 more countries
Ages 18–99
University of Zurich · Sites in Switzerland
Ages 18–50 · Healthy volunteers
The Cleveland Clinic · Sites in Switzerland, United States, Brazil and 10 more countries
Ages 18–75 · Healthy volunteers
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 45 Years to 60 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 2 · Phase 3 16 · Phase 4 5
First in 1998; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 84 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 64 across the 90 interventional studies, 85 across the 37 observational. Of the 85 that completed or were terminated, 2 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 127 have an industry lead sponsor. The 10 most frequent:
University Hospital, Geneva is the lead sponsor of 379 studies on the registry; 70 are open to participants now.
University Hospital, Geneva has 8 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
10 of the studies in Obesity with a site in Switzerland that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT04234373University Hospital, Basel, SwitzerlandEffect of a Low-carb Dietary Intervention in Obese Patients: a Pilot Trial | 2026-12 |
| NCT02902198University Hospital, Basel, SwitzerlandTaste Physiology in Obese Volunteers Before and After Bariatric Surgery | 2026-12 |
| NCT06546384Insel Gruppe AG, University Hospital BernGLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 127 studies in Obesity with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is aimed at women currently going through menopause, either as part of the natural process (physiological menopause), or following hormonal treatment for breast cancer. There are several ways of slowing the weight gain frequently encountered in this situation, reducing the intensity of menopause-related symptoms and improving quality of life in this context.
In this trial, the investigators examine the efficacy and possible adverse effects of intermittent fasting compared with a control intervention. Participation lasts 14 weeks, with an optional 12-month follow-up. Study participants are randomly assigned to either the intervention group or the control group. In the intervention group, study participants fast for 16 hours per day and eat over a period of 8 hours (intermittent fasting often called time-restricted eating [TRE] 16h/8h). In the control group, the usual eating pattern is continued for 12 weeks.
The main objective of the study is to evaluate the efficacy of TRE in terms of weight and fat loss, improvement in metabolic profile, menopausal symptoms and bone health. In addition, the study team closely monitors any adverse effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: Time-Restricted Eating 16h/8h
Behavioral: Active Control
Participants will be advised to eat only during a self-selected window of 8 hours over the 24-hour cycle, with a 1-hour allowance according to their daily routine.
Also known as: TRE 16h/8h
Participants will be advised to eat 2 to 3 meals every day according to their eating habits and social activities
Changes in body weight
Measured (in Kg) in light clothing using a calibrated medical-grade scale
Time frame: From randomization visit to close-out visit (12 weeks)
Changes in body fat mass
Measured (in Kg) by dual-energy x-ray absorptiometry (DXA)
Time frame: From randomization visit to close-out visit (12 weeks)
Changes in menopause / climacteric symptoms
Assessed by questionnaire
Time frame: From randomization visit to close-out visit (12 weeks)
Changes in bone mineral density
Measured (in g/cm3) by dual-energy x-ray absorptiometry (DXA)
Time frame: From randomization visit to close-out visit (12 weeks)
Changes in bone turnover marker CTX
C-telopeptide cross-linked type 1 collagen (CTX) measured (in ng/L) by clinical chemistry
Time frame: From randomization visit to close-out visit (12 weeks)
Changes in bone turnover marker P1NP
Procollagen type 1 N-terminal propeptide (P1NP) measured (in μg/L) by clinical chemistry
Time frame: From randomization visit to close-out visit (12 weeks)
Changes in joint pain
Joint pain assessed by questionnaire (0 = absent to 7 = Extremely bothered)
Time frame: From randomization visit to close-out visit (12 weeks)
Changes in body mass index (BMI)
Expressed in percent of baseline value (body mass index = weight in Kg divided by the height in meters squared, unit Kg/m2)
Time frame: From randomization visit to close-out visit (12 weeks)
Changes in waist circumference
Measured (in cm) with a measuring tape, following the WHO 2008 Expert Report
Time frame: From randomization visit to close-out visit (12 weeks)
Changes in hip circumference
Measured (in cm) with a measuring tape, following the WHO 2008 Expert Report
Time frame: From randomization visit to close-out visit (12 weeks)
Changes in systolic and diastolic blood pressure
Measured (in mmHg) with an arm cuff in the sitting position
Time frame: From randomization visit to close-out visit (12 weeks)
Changes in fasting plasma glucose
Measured (in mmol/L) by clinical chemistry
Time frame: From randomization visit to close-out visit (12 weeks)
Changes in lipid profile
Total cholesterol, LDL cholesterol, triglycerides and HDL cholesterol concentrations measured (in mmol/L) by clinical chemistry
Time frame: From randomization visit to close-out visit (12 weeks)
Changes in lean body mass
Measured (in Kg) by dual-energy x-ray absorptiometry (DXA)
Time frame: From randomization visit to close-out visit (12 weeks)
Changes in body composition
Fat mass and fat-free mass (in Kg) measured by bioelectrical impedance analysis (BIA)
Time frame: From randomization visit to close-out visit (12 weeks)
Changes in muscle function
Measured (in Kg) by handgrip strength
Time frame: From randomization visit to close-out visit (12 weeks)
Changes in glucose excursion
Measured by continuous glucose monitoring
Time frame: From randomization visit to close-out visit (12 weeks)
Changes in metabolomic profile
Measured by high-throughput mass spectrometry metabolomics
Time frame: From randomization visit to close-out visit (12 weeks)
Changes in physical activity
Measured by actigraphy (in activity counts, CamNTech proprietary algorithm) and by the International Physical Activity Questionnaire (IPAQ, aggregated in MET-minutes/week)
Time frame: From randomization visit to close-out visit (12 weeks)
Changes in sleep/wake cycles
Measured by actigraphy assessed as time of sleep onset and wake-up in 24-hour cycle
Time frame: From randomization visit to close-out visit (12 weeks)
Changes in sleep duration
Measured by actigraphy
Time frame: From randomization visit to close-out visit (12 weeks)
Changes in body temperature
Measured by body temperature wearable device
Time frame: From randomization visit to close-out visit (12 weeks)
Changes in sleep quality
Assessed by the Pittsburgh Sleep Quality Index \[PSQI, minimum score = 0 (better); maximum score = 21 (worse)\]
Time frame: From randomization visit to close-out visit (12 weeks)
Changes in eating duration
Duration from the first to last caloric intake over 24-hour cycle
Time frame: From randomization visit to close-out visit (12 weeks)
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Mar 2027, 22 months after the start.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 22 months is close to that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.